Myungmoon Phar Asset Resilience Ratio

Latest as of December 2025: 0.11%

Myungmoon Phar asset resilience ratio. Myungmoon Phar (017180) has an Asset Resilience Ratio of 0.11% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Myungmoon Phar liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩309.32 Million
≈ $209.63K USD Cash + Short-term Investments

Total Assets

₩272.46 Billion
≈ $184.64 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Myungmoon Phar (2009–2025)

Asset resilience ratio of Myungmoon Phar from 2009 to 2025. This chart shows how Myungmoon Phar's Asset Resilience Ratio has changed over time. Read Myungmoon Phar total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Myungmoon Phar's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Myungmoon Phar (017180) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩309.32 Million 0.11%
Total Liquid Assets ₩309.32 Million 0.11%

Asset Resilience Insights

  • Limited Liquidity: Myungmoon Phar maintains only 0.11% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Myungmoon Phar Industry Peers by Asset Resilience Ratio

Compare Myungmoon Phar's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 26.45%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 11.84%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Bide Pharmatech Co. Ltd. A
SHG:688073
Drug Manufacturers - Specialty & Generic 9.46%
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
Drug Manufacturers - Specialty & Generic 20.61%
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
Drug Manufacturers - Specialty & Generic 30.38%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.42%

Myungmoon Phar Asset Resilience Ratio by Year (2009–2025)

Myungmoon Phar asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Myungmoon Phar.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.11% ₩309.32 Million
≈ $209.63K
₩272.46 Billion
≈ $184.64 Million
-0.03pp
2024-12-31 0.14% ₩365.41 Million
≈ $247.63K
₩257.99 Billion
≈ $174.83 Million
-1.42pp
2023-12-31 1.57% ₩3.70 Billion
≈ $2.51 Million
₩236.55 Billion
≈ $160.31 Million
-0.66pp
2022-12-31 2.22% ₩5.13 Billion
≈ $3.47 Million
₩230.45 Billion
≈ $156.17 Million
+0.56pp
2021-12-31 1.66% ₩3.70 Billion
≈ $2.51 Million
₩222.68 Billion
≈ $150.90 Million
-1.85pp
2020-12-31 3.51% ₩8.53 Billion
≈ $5.78 Million
₩243.03 Billion
≈ $164.69 Million
+0.41pp
2019-12-31 3.10% ₩8.19 Billion
≈ $5.55 Million
₩264.44 Billion
≈ $179.21 Million
-0.35pp
2018-12-31 3.45% ₩8.39 Billion
≈ $5.68 Million
₩243.07 Billion
≈ $164.72 Million
+0.29pp
2017-12-31 3.16% ₩7.43 Billion
≈ $5.03 Million
₩235.08 Billion
≈ $159.31 Million
+1.07pp
2016-12-31 2.09% ₩4.62 Billion
≈ $3.13 Million
₩221.08 Billion
≈ $149.82 Million
-0.97pp
2015-12-31 3.07% ₩6.11 Billion
≈ $4.14 Million
₩199.42 Billion
≈ $135.14 Million
-1.22pp
2014-12-31 4.28% ₩8.17 Billion
≈ $5.53 Million
₩190.66 Billion
≈ $129.21 Million
-0.35pp
2013-12-31 4.64% ₩8.92 Billion
≈ $6.05 Million
₩192.41 Billion
≈ $130.39 Million
+0.53pp
2012-12-31 4.10% ₩7.73 Billion
≈ $5.24 Million
₩188.34 Billion
≈ $127.63 Million
+1.93pp
2011-12-31 2.18% ₩4.41 Billion
≈ $2.99 Million
₩202.50 Billion
≈ $137.23 Million
-3.91pp
2010-12-31 6.08% ₩9.99 Billion
≈ $6.77 Million
₩164.15 Billion
≈ $111.24 Million
+5.50pp
2009-12-31 0.58% ₩890.00 Million
≈ $603.14K
₩153.85 Billion
≈ $104.26 Million
--
pp = percentage points

About Myungmoon Phar

KO:017180 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$25.63 Million
₩37.82 Billion KRW
Market Cap Rank
#24113 Global
#1697 in Korea
Share Price
₩1114.00
Change (1 day)
-1.76%
52-Week Range
₩1057.00 - ₩1945.00
All Time High
₩10277.86
About

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more